Works matching IS 01676997 AND DT 2015 AND VI 33 AND IP 1

Results: 32

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.

Published in:

2015

By:

Ku, Bo;
Jho, Eun;
Bae, Yeon-Hee;
Sun, Jong-Mu;
Ahn, Jin;
Park, Keunchil;
Ahn, Myung-Ju

Publication type:

Journal Article

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

Published in:

2015

By:

LoConte, Noelle;
Razak, Albiruni;
Ivy, Percy;
Tevaarwerk, Amye;
Leverence, Rachael;
Kolesar, Jill;
Siu, Lillian;
Lubner, Sam;
Mulkerin, Daniel;
Schelman, William;
Deming, Dustin;
Holen, Kyle;
Carmichael, Lakeesha;
Eickhoff, Jens;
Liu, Glenn

Publication type:

Journal Article

Successful treatment of Evans syndrome with Tacrolimus.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 254, doi. 10.1007/s10637-014-0155-9

By:

Tabchi, Samer;
Hanna, Colette;
Kourie, Hampig;
Aftimos, Philippe;
Osta, Lana;
Ghosn, Marwan

Publication type:

Article

Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 1, doi. 10.1007/s10637-014-0156-8

By:

Zhang, Chris;
Fang, Evandro;
Zhang, Hai-Tao;
Liu, Li-Li;
Yun, Jing-Ping

Publication type:

Article

Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 109, doi. 10.1007/s10637-014-0157-7

By:

Beane, Joal;
Griffin, Kayla;
Levy, Elliot;
Pandalai, Prakash;
Wood, Bradford;
Abi-Jaoudeh, Nadine;
Beresnev, Tatiana;
Shutack, Yvonne;
Webb, Carole;
Avital, Itzhak;
Rudloff, Udo

Publication type:

Article

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 148, doi. 10.1007/s10637-014-0160-z

By:

Jotte, Robert;
Von Hoff, Daniel;
Braiteh, Fadi;
Becerra, Carlos;
Richards, Donald;
Smith, David;
Garbo, Lawrence;
Stephenson, Joe;
Conkling, Paul;
Robert-Vizcarrondo, Francisco;
Chen, Jian;
Turner, P.;
Chow, Kay;
Tai, D.;
Ilaria, Robert

Publication type:

Article

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 119, doi. 10.1007/s10637-014-0161-y

By:

Mukai, Hirofumi;
Saeki, Toshiaki;
Shimada, Ken;
Naito, Yoichi;
Matsubara, Nobuaki;
Nakanishi, Tadashi;
Obaishi, Hiroshi;
Namiki, Masayuki;
Sasaki, Yasutsuna

Publication type:

Article

Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Published in:

2015

By:

Lee, Jeeyun;
Hong, Yong;
Hong, Jung;
Han, Se;
Kim, Tae;
Kang, Hye;
Kim, Kyu-pyo;
Kim, Suk;
Do, In-Gu;
Kim, Kyoung-Mee;
Sohn, Insuk;
Park, Se;
Park, Joon;
Lim, Ho;
Cho, Yong;
Lee, Woo;
Yun, Seong;
Kim, Hee;
Park, Young;
Kang, Won

Publication type:

Erratum

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 12, doi. 10.1007/s10637-014-0163-9

By:

Ku, Bo;
Jho, Eun;
Bae, Yeon-Hee;
Sun, Jong-Mu;
Ahn, Jin;
Park, Keunchil;
Ahn, Myung-Ju

Publication type:

Article

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 128, doi. 10.1007/s10637-014-0164-8

By:

Goyal, Lipika;
Wadlow, Raymond;
Blaszkowsky, Lawrence;
Wolpin, Brian;
Abrams, Thomas;
McCleary, Nadine;
Sheehan, Susan;
Sundaram, Eamala;
Karol, Michael;
Chen, John;
Zhu, Andrew

Publication type:

Article

Acetylamine derivative of diospyrin, a plant-derived binaphthylquinonoid, inhibits human colon cancer growth in Nod-Scid mice.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 22, doi. 10.1007/s10637-014-0165-7

By:

Hazra, Sudipta;
Ghosh, Subhalakshmi;
Kumar, Amit;
Pandey, B.;
Hazra, Banasri

Publication type:

Article

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 169, doi. 10.1007/s10637-014-0166-6

By:

LoConte, Noelle;
Razak, Albiruni;
Ivy, Percy;
Tevaarwerk, Amye;
Leverence, Rachael;
Kolesar, Jill;
Siu, Lillian;
Lubner, Sam;
Mulkerin, Daniel;
Schelman, William;
Deming, Dustin;
Holen, Kyle;
Carmichael, Lakeesha;
Eickhoff, Jens;
Liu, Glenn

Publication type:

Article

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 177, doi. 10.1007/s10637-014-0173-7

By:

Falchook, Gerald;
Moulder, Stacy;
Naing, Aung;
Wheler, Jennifer;
Hong, David;
Piha-Paul, Sarina;
Tsimberidou, Apostolia;
Fu, Siqing;
Zinner, Ralph;
Janku, Filip;
Jiang, Yunfang;
Huang, Mei;
Parkhurst, Kristin;
Kurzrock, Razelle

Publication type:

Article

Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 32, doi. 10.1007/s10637-014-0168-4

By:

Mrusek, Marco;
Seo, Ean-Jeong;
Greten, Henry;
Simon, Michael;
Efferth, Thomas

Publication type:

Article

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 241, doi. 10.1007/s10637-014-0169-3

By:

Knox, Jennifer;
Qin, Rui;
Strosberg, Jonathan;
Tan, Benjamin;
Kaubisch, Andreas;
El-Khoueiry, Anthony;
Bekaii-Saab, Tanios;
Rousey, Steven;
Chen, Helen;
Erlichman, Charles

Publication type:

Article

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 194, doi. 10.1007/s10637-014-0170-x

By:

Iguchi, Haruo;
Nishina, Tomohiro;
Nogami, Naoyuki;
Kozuki, Toshiyuki;
Yamagiwa, Yumiko;
Yagawa, Katsuro

Publication type:

Article

Novel benzoxazines as inhibitors of angiogenesis.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 45, doi. 10.1007/s10637-014-0172-8

By:

Al-Rawi, Sara;
Meehan-Andrews, Terri;
Bradley, Chris;
Al-Rawi, Jasim

Publication type:

Article

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5

By:

Puzanov, Igor;
Sosman, Jeffrey;
Santoro, Armando;
Saif, Muhammad;
Goff, Laura;
Dy, Grace;
Zucali, Paolo;
Means-Powell, Julie;
Ma, Wen;
Simonelli, Matteo;
Martell, Robert;
Chai, Feng;
Lamar, Maria;
Savage, Ronald;
Schwartz, Brian;
Adjei, Alex

Publication type:

Article

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 225, doi. 10.1007/s10637-014-0174-6

By:

Ngamphaiboon, Nuttapong;
Dy, Grace;
Ma, Wen;
Zhao, Yujie;
Reungwetwattana, Thanyanan;
DePaolo, Dawn;
Ding, Yi;
Brady, William;
Fetterly, Gerald;
Adjei, Alex

Publication type:

Article

Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 53, doi. 10.1007/s10637-014-0175-5

By:

Bergamo, Alberta;
Riedel, Tina;
Dyson, Paul;
Sava, Gianni

Publication type:

Article

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 215, doi. 10.1007/s10637-014-0176-4

By:

Falchook, Gerald;
Wheler, Jennifer;
Naing, Aung;
Piha-Paul, Sarina;
Fu, Siqing;
Tsimberidou, Apostolia;
Hong, David;
Janku, Filip;
Zinner, Ralph;
Jiang, Yunfang;
Huang, Mei;
Lin, Quan;
Parkhurst, Kristin;
Kurzrock, Razelle

Publication type:

Article

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 187, doi. 10.1007/s10637-014-0177-3

By:

Bendell, Johanna;
Jones, Suzanne;
Hart, Lowell;
Spigel, David;
Lane, Cassie;
Earwood, Chris;
Infante, Jeffrey;
Barton, John;
Burris, Howard

Publication type:

Article

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 257, doi. 10.1007/s10637-014-0178-2

By:

Narjoz, C.;
Cessot, A.;
Thomas-Schoemann, A.;
Golmard, J.;
Huillard, O.;
Boudou-Rouquette, P.;
Behouche, A.;
Taieb, F.;
Durand, J.;
Dauphin, A.;
Coriat, R.;
Vidal, M.;
Tod, M.;
Alexandre, J.;
Loriot, M.;
Goldwasser, F.;
Blanchet, B.

Publication type:

Article

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 201, doi. 10.1007/s10637-014-0179-1

By:

Leijen, Suzanne;
Burgers, Sjaak;
Baas, Paul;
Pluim, Dick;
Tibben, Matthijs;
Werkhoven, Erik;
Alessio, Enzo;
Sava, Gianni;
Beijnen, Jos;
Schellens, Jan

Publication type:

Article

Pharmacokinetics and excretion of C-lenvatinib in patients with advanced solid tumors or lymphomas.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 233, doi. 10.1007/s10637-014-0181-7

By:

Dubbelman, Anne-Charlotte;
Rosing, Hilde;
Nijenhuis, Cynthia;
Huitema, Alwin;
Mergui-Roelvink, Marja;
Gupta, Anubha;
Verbel, David;
Thompson, Gary;
Shumaker, Robert;
Schellens, Jan;
Beijnen, Jos

Publication type:

Article

Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 64, doi. 10.1007/s10637-014-0182-6

By:

Ali Azouaou, Sarah;
Emhemmed, Fathi;
Idris-Khodja, Noureddine;
Lobstein, Annelise;
Schini-Kerth, Valérie;
Muller, Christian;
Fuhrmann, Guy

Publication type:

Article

Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 75, doi. 10.1007/s10637-014-0184-4

By:

Ouchani, Farid;
Jeanne, Albin;
Thevenard, Jessica;
Helesbeux, Jean-Jacques;
Wahart, Amandine;
Letinois, Isabelle;
Duval, Olivier;
Martiny, Laurent;
Charpentier, Emmanuelle;
Devy, Jérôme

Publication type:

Article

The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 86, doi. 10.1007/s10637-014-0185-3

By:

Guzmán, Esther;
Maers, Kelly;
Roberts, Jill;
Kemami-Wangun, Hilaire;
Harmody, Dedra;
Wright, Amy

Publication type:

Article

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 247, doi. 10.1007/s10637-014-0186-2

By:

Schiff, David;
Kesari, Santosh;
Groot, John;
Mikkelsen, Tom;
Drappatz, Jan;
Coyle, Thomas;
Fichtel, Lisa;
Silver, Bruce;
Walters, Ian;
Reardon, David

Publication type:

Article

In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 95, doi. 10.1007/s10637-014-0187-1

By:

Ouellet, Charles;
Ouellet, Étienne;
Poirier, Donald

Publication type:

Article

4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 104, doi. 10.1007/s10637-014-0188-0

By:

Fazio, Pietro;
Lingelbach, Susanne;
Schobert, Rainer;
Biersack, Bernhard

Publication type:

Article

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 138, doi. 10.1007/s10637-014-0142-1

By:

Bennouna, Jaafar;
Deslandres, Marion;
Senellart, Helene;
Labareyre, Cecile;
Ruiz-Soto, Rodrigo;
Wixon, Claire;
Botbyl, Jeff;
Suttle, A.;
Delord, Jean-Pierre

Publication type:

Article